Tristan T Sands1, Tiffani L McDonough2. 1. Division of Child Neurology, Columbia University Medical Center, 180 Fort Washington Avenue, New York, NY, 10032, USA. 2. Division of Child Neurology, Columbia University Medical Center, 180 Fort Washington Avenue, New York, NY, 10032, USA. tm2714@cumc.columbia.edu.
Abstract
PURPOSE OF REVIEW: This article strives to review and summarize selected recent literature and topics contributing to a greater understanding of the diagnosis and treatments of neonatal seizures that have emerged in the past several years. RECENT FINDINGS: Continuous EEG is recommended as the gold standard for neonatal seizure monitoring as it can provide additional information that may stratify patients by etiology, as well as identify at-risk groups of newborns for neuromonitoring. Investigations are moving beyond traditional antiepileptic agents in search of treatments with better efficacy and with less concern for developmental effects. Targeted therapies for seizures resulting from particular genetic conditions are increasing, highlighting the importance of early genetic diagnosis. Better understanding of the risk of post-neonatal epilepsy based on etiology is emerging with new epidemiological studies. Evidence is growing for deleterious effects of seizures on outcomes, elevating the importance of seizure detection and effective treatment. Advances in utilization of continuous EEG monitoring have improved the accuracy of seizure detection and have identified at-risk groups of newborns for neuromonitoring. Ultimately, the goal in management of neonatal seizures is not only clinical stabilization in the acute period but also to influence neurodevelopmental outcome and modify the risk of future epilepsy.
PURPOSE OF REVIEW: This article strives to review and summarize selected recent literature and topics contributing to a greater understanding of the diagnosis and treatments of neonatal seizures that have emerged in the past several years. RECENT FINDINGS: Continuous EEG is recommended as the gold standard for neonatal seizure monitoring as it can provide additional information that may stratify patients by etiology, as well as identify at-risk groups of newborns for neuromonitoring. Investigations are moving beyond traditional antiepileptic agents in search of treatments with better efficacy and with less concern for developmental effects. Targeted therapies for seizures resulting from particular genetic conditions are increasing, highlighting the importance of early genetic diagnosis. Better understanding of the risk of post-neonatal epilepsy based on etiology is emerging with new epidemiological studies. Evidence is growing for deleterious effects of seizures on outcomes, elevating the importance of seizure detection and effective treatment. Advances in utilization of continuous EEG monitoring have improved the accuracy of seizure detection and have identified at-risk groups of newborns for neuromonitoring. Ultimately, the goal in management of neonatal seizures is not only clinical stabilization in the acute period but also to influence neurodevelopmental outcome and modify the risk of future epilepsy.
Authors: Mary J Harbert; Emily W Y Tam; Hannah C Glass; Sonia L Bonifacio; Laurel A Haeusslein; A James Barkovich; Rita J Jeremy; Elizabeth E Rogers; David V Glidden; Donna M Ferriero Journal: J Child Neurol Date: 2011-06-23 Impact factor: 1.987
Authors: Grace E Kim; Jack Kronengold; Giulia Barcia; Imran H Quraishi; Hilary C Martin; Edward Blair; Jenny C Taylor; Olivier Dulac; Laurence Colleaux; Rima Nabbout; Leonard K Kaczmarek Journal: Cell Rep Date: 2014-12-04 Impact factor: 9.423
Authors: Clara D M van Karnebeek; Sylvia A Tiebout; Jikkemien Niermeijer; Bwee Tien Poll-The; Aisha Ghani; Curtis R Coughlin; Johan L K Van Hove; Jost Wigand Richter; Hans Juergen Christen; Renata Gallagher; Hans Hartmann; Sylvia Stockler-Ipsiroglu Journal: Pediatr Neurol Date: 2016-01-11 Impact factor: 3.372
Authors: D M Murray; G B Boylan; I Ali; C A Ryan; B P Murphy; S Connolly Journal: Arch Dis Child Fetal Neonatal Ed Date: 2007-07-11 Impact factor: 5.747
Authors: Evonne Low; Sean R Mathieson; Nathan J Stevenson; Vicki Livingstone; C Anthony Ryan; Conor O Bogue; Janet M Rennie; Geraldine B Boylan Journal: PLoS One Date: 2014-07-22 Impact factor: 3.240
Authors: Ragna S Boerma; Kees P Braun; Marcel P H van den Broek; Maarten P H van de Broek; Frederique M C van Berkestijn; Marielle E Swinkels; Eveline O Hagebeuk; Dick Lindhout; Marjan van Kempen; Maartje Boon; Joost Nicolai; Carolien G de Kovel; Eva H Brilstra; Bobby P C Koeleman Journal: Neurotherapeutics Date: 2016-01 Impact factor: 7.620
Authors: Sean M M Quinlan; Natalia Rodriguez-Alvarez; Eleanor J Molloy; Stephen F Madden; Geraldine B Boylan; David C Henshall; Eva M Jimenez-Mateos Journal: Sci Rep Date: 2018-07-03 Impact factor: 4.379
Authors: Serena Pellegrin; Flor M Munoz; Michael Padula; Paul T Heath; Lee Meller; Karina Top; Jo Wilmshurst; Max Wiznitzer; Manoja Kumar Das; Cecil D Hahn; Merita Kucuku; James Oleske; Kollencheri Puthenveettil Vinayan; Elissa Yozawitz; Satinder Aneja; Niranjan Bhat; Geraldine Boylan; Sanie Sesay; Anju Shrestha; Janet S Soul; Beckie Tagbo; Jyoti Joshi; Aung Soe; Helena C Maltezou; Jane Gidudu; Sonali Kochhar; Ronit M Pressler Journal: Vaccine Date: 2019-12-10 Impact factor: 3.641